Enlaza Therapeutics
Latest round
- Series A
Last raised
- Apr 2024
Total raised
- $196M
Investors
- 10
About Enlaza Therapeutics
, operates as a biotechnology company that develops protein therapeutics to create drugs for cancer and other serious diseases. The company offers a healthcare platform, War-LockTM, that provides protein therapeutics used for the treatment of cancer and other serious diseases by minimizing exposure to healthy tissues. The drug is influenced by the company's proprietary amino acid subunits, which form a covalent bond between the drug and the target. In April 2024, Enlaza Therapeutics, Inc., and Samsara BioCapital.
Who invested in Enlaza Therapeutics
10 investors across 3 rounds
See all investors in Enlaza Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Enlaza Therapeutics
Who invested in Enlaza Therapeutics?
Enlaza Therapeutics has 10 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Enlaza Therapeutics raised?
Enlaza Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Enlaza Therapeutics last raise money?
Enlaza Therapeutics's most recent round on record is a Series A, in Apr 2024.
What does Enlaza Therapeutics do?
, operates as a biotechnology company that develops protein therapeutics to create drugs for cancer and other serious diseases.
Where is Enlaza Therapeutics headquartered?
Enlaza Therapeutics is headquartered in La Jolla, US.
Which VCs invest in companies like Enlaza Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Enlaza Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Enlaza Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.